- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00490113
A Trial of Pyridoxamine to Lower Urine Oxalate in Subjects With Stone Disease or Hyperoxaluria
January 3, 2017 updated by: University of Kansas Medical Center
Effects of Pyridoxamine on Oxalate Excretion in Stone Disease and Hyperoxaluria
To determine whether pyridoxamine can decrease oxalate excretion in subjects who have normal oxalate excretion (but who have had kidney stones), and in subjects who have primary hyperoxaluria.
Study Overview
Study Type
Interventional
Phase
- Phase 2
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Adults > 18 years
- History of stone formation
- Good Renal function
- Normal urinary excretion of stone-promoting chemicals(Ca, uric acid, oxalate, citrate), except for subjects with hyperoxaluria for Study
Exclusion Criteria:
- Pregnancy
- Hyperparathyroidism
- Enteric hyperoxaluria.
- Obstructive uropathy
- Infection (struvite) stones
- Severe dietary Ca++ restriction or deficiency
- Recent significant cardio-vascular events
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 1
|
Two 250 mg capsules, or placebo, given twice a day for four, 4 week periods.
Subjects with primary hyperoxaluria will aslo receive escalated doses up to 3500 mg/day for up to 6 1/2 days.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Urinary Excretion of Oxalate at Highest Dose
Time Frame: 4 Weeks
|
4 Weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change in Urinary Supersaturation
Time Frame: 4 Weeks
|
4 Weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Jon I Scheinman, M.D., University of Kansas Medical Center
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
January 1, 2007
Study Registration Dates
First Submitted
June 20, 2007
First Submitted That Met QC Criteria
June 21, 2007
First Posted (Estimate)
June 22, 2007
Study Record Updates
Last Update Posted (Estimate)
January 5, 2017
Last Update Submitted That Met QC Criteria
January 3, 2017
Last Verified
January 1, 2017
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 10417 (Other Identifier: Fred Hutch/University of Washington Cancer Consortium)
- 1R21DK072454-02 (U.S. NIH Grant/Contract)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Kidney Stones
-
Indiana Kidney Stone InstituteUniversity of Washington; VA Puget Sound Health Care SystemCompleted
-
Omeros CorporationCompletedUrinary Calculi | Renal Calculi | Kidney Stones | Urinary Stones | Urinary Tract StonesUnited States
-
Mayo ClinicCompletedKidney Calculi | Nephrolithiasis | Kidney Stones | Renal StonesUnited States, Canada
-
University of British ColumbiaPercutaneous Systems, Inc.Completed
-
United States Naval Medical Center, San DiegoUnknown
-
Robert SworWilliam Beaumont HospitalsCompletedKidney Stones | Ureteral StonesUnited States
-
Mansoura UniversityUnknownUrologic Diseases | Stones, Kidney | Stone, Urinary | Shock Wave LithotripsyEgypt
-
Mansoura UniversityRecruitingUrinary Stones | Renal StoneEgypt
-
Services Hospital, LahoreCompleted
-
Adva-TecUniversity of British ColumbiaCompletedUnilateral Ureteral Stone | Renal Stone Fragments ≤ 2mmCanada
Clinical Trials on Pyridoxamine
-
NephroGenex, Inc.Medpace, Inc.; Collaborative Study Group (CSG)TerminatedDiabetic Nephropathy | Diabetic Kidney DiseaseUnited States, Australia, Bulgaria, France, Germany, Hong Kong, Hungary, Israel, Mauritius, Poland, Puerto Rico, Spain
-
Columbia UniversityCompletedDiabetes Mellitus, Type 2United States
-
NephroGenex, Inc.Medpace, Inc.; Collaborative Study Group (CSG)CompletedDiabetic NephropathyUnited States
-
Maastricht University Medical CenterDiabetes FondsRecruitingType 2 Diabetes | Neuropathy, Diabetic | Nephropathy, Diabetic | Microvascular Function | Retinopathy, DiabeticNetherlands
-
Maastricht University Medical CenterCenter for Translational Molecular Medicine; Top Institute Food and NutritionCompletedAbdominal Obesity Metabolic SyndromeNetherlands